OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.
OrsoBio has raised $67.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
OrsoBio's investors include Eli Lilly, Samsara BioCapital, Longitude Capital, Enavate Sciences, Woodline Partners.
OrsoBio is headquartered in Palo Alto, United States.
OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.
OrsoBio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OrsoBio — Funding & Investors." VCBacked, September 6, 2024, https://www.vcbacked.co/company/orsobio. Accessed July 29, 2026.
VCBacked. (2024). OrsoBio — Funding & Investors. Retrieved July 29, 2026, from https://www.vcbacked.co/company/orsobio
{{cite web |title=OrsoBio — Funding & Investors |url=https://www.vcbacked.co/company/orsobio |website=VCBacked |access-date=July 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated